| Part I: prediction that LATS2 is a potential target gene of hsa-mir-373-3pObjective: to search for the targeting relationship between hsa-mir-373-3p and LATS2 gene by logging online or downloading the bioinformatics prediction software,and to explore whether LATS2 is the target gene of hsa-mir-373-3p.Relevant literatures were reviewed to determine whether LATS2 is a functional target of hsa-mir-373-3p and whether there is a targeted regulatory relationship between hsa-mir-373-3p and LATS2.Methods: 1.MiRbase was used to obtain the base sequence of hsa-mir-373-3p;2.Target Scan,miRDB,miRTarBase,miRWalk,microRNA.org and other online software were used to find the targeted relationship between hsa-mir-373-3p and LATS2 gene.2.Relevant literatures on hsa-mir-373-3p and LATS2 were reviewed in domestic and foreign databases to find whether studies have verified the targeted regulatory relationship between hsa-mir-373-3p and LATS2.Results:1.Four bioinformatics software,TargetScan,miRDB,miRTarBase,miRWalk and microRNA.org,were able to predict online that LATS2 was a target gene of hsa-mir-373-3p.2.Foreign studies on esophageal squamous cellcarcinoma and testicular germ cell tumor reported a targeted relationship between hsa-mir-373-3p and LATS2,which verified that LATS2 was a direct functional target of hsa-mir-373-3p.Hsa-mir-373-3p regulates the expression of LATS2 in a targeted manner.Conclusion: 1.LATS2 is a direct functional target of hsa-mir-373-3p,and there is a targeting relationship between the two.Hsa-mir-373-3p can regulate the expression of LATS2.Part II: study on the expression changes of hsa-mir-373-3p and LATS2 in endometrial cancer tissuesObjective: 1.To investigate the expressions of hsa-mir-373-3p and the predicted target gene LATS2 in endometrial cancer tissues and normal endometrial tissues,and to analyze the correlation between them according to the differences in the expressions of hsa-mir-373-3p and LATS2,and to preliminarily study the significance of the two in the pathogenesis of endometrial cancer.2.The correlation between hsa-mir-373-3p and the clinicopathological factors(such as pathological type,clinicopathologic stage,histological grade,muscle invasion depth,lymph node metastasis,distant metastasis,etc.)in endometrial cancer patients was analyzed according to the difference in relative expression of hsa-mir-373-3p in endometrial cancer tissues and normal endometrial tissues.Methods:1,collected in September,2016-December 2017 in our hospital by pathological diagnosis of endometrial carcinoma in patients with surgical specimens from 30 cases as the experimental group,20 cases of normal tissue adjacent to carcinoma as normal control,application of real-time fluorescent quantitative PCR(real time PCR,quantity q RT-PCR)detection in patients with endometrial cancer tissue and normal tissue adjacent to carcinoma in hsa-miR-373-3 p with LATS2 expression,at the same time complementary with protein immunoblot method(Western Blotting.WB)to detect the expression levels of LATS2 in endometrial carcinoma tissues and normal endometrial tissues,and SPSS22.0 statistical software was used to calculate and verify the relative expression differences of hsa-mir-373-3p and LATS2 in endometrial carcinoma tissues and adjacent normal tissues.The correlation between hsa-mir-373-3p and LATS2 in endometrial cancer tissues was analyzed by rank correlation analysis.2.According to the differences in the expression of hsa-mir-373-3p in different endometrial cancer tissues,univariate anova was used to understand the correlation between the clinical and pathological parameters of hsa-mir-373-3p and endometrial cancer patients.Results: 1.PCR results suggested that the relative expression levels of hsa-mir-373-3p in endometrial cancer tissues and normal endometrial tissues were 3.045±1.664 and 1.098±0.419,respectively.The relative expression levels of LATS2 in endometrial cancer and normal endometrial tissues were0.728±0.55 and 0.201±0.188,respectively.Compared with normal tissues adjacent to cancer,the expression of hsa-mir-373-3p was up-regulated in endometrial cancer tissues,while the expression of LATS2 was down-regulated in endometrial cancer tissues,with statistically significant difference(t=2.539,P<0.01).WB results showed that compared with normal endometrial tissues,the expression of LATS2 in endometrial carcinoma tissues was down-regulated.The negative correlation between hsa-mir-373-3p and LATS2 was significant.It was preliminarily concluded that LATS2 may be involved in the development of endometrial cancer as a direct functional target of hsa-mir-373-3p,and that hsa-mir-373-3p may play a role in the pathogenesis of endometrial cancer by targeting and regulating the expression of LATS2.2.The expression level of hsa-mir-373-3p was 2.251 0.976 and 4.437±1.718,respectively,in the tissues of patients with stage I and II/III endometrial cancer.In patients with high,medium and low differentiation endometrial cancer,the differences were(2.114±0.769,3.111±1.732,4.755±1.525).The expression levels in the tissues of patients with and without pelvic lymph node metastasis endometrial cancer were(4.465±1.589,2.263±1.455).The expression levels of endometrial cancer tissues with muscle invasion depth 1/2 and < 1/2 were respectively(4.598±1.685 and2.28±0.989),and the differences were statistically significant(P < 0.05),indicating that the relative expression level of hsa-mir-373-3p was closely related to the degree of malignancy of endometrial cancer.Conclusion: 1,hsa-miR-373-3p in endometrial carcinoma tissue increased,prompt hsa-miR-373-3p may occur in endometrial cancer development play an important role that promote cancer gene,the lower the express LATS2 in endometrial carcinoma tissue,hsa-miR-373-3p with LATS2 has significant negative correlation,and LATS2 as hsa-miR-373-3p target genes,we can preliminary think has-miR-373-3p may be targeted by regulating LATS2 is involved in the pathogenesis of endometrial cancer,In the development of endometrial cancer plays a regulatory role.2.There was a significant correlation between hsa-mir-373-3p and the clinicopathological characteristics of patients with endometrial cancer.The expression level of hsa-mir-373-3p was positively correlated with histological grading,clinicopathological staging,muscle infiltration depth and the presence or absence of lymph node metastasis,indicating that hsa-mir-373-3p may be a gene to evaluate the degree of malignancy of endometrial cancer.Hsa-mir-373-3p can be used as a special marker for the treatment of endometrial cancer,which has important reference significance for the potential therapeutic targets and prognosis of endometrial cancer. |
PDF Full Text Request